BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/25/2023 11:32:55 PM | Browse: 166 | Download: 414
 |
Received |
|
2022-09-19 19:58 |
|
Peer-Review Started |
|
2022-09-19 20:00 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-10-24 07:15 |
|
Revised |
|
2023-02-07 15:32 |
|
Second Decision |
|
2023-03-24 02:57 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-03-24 05:58 |
|
Articles in Press |
|
2023-03-24 05:58 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-04-10 12:19 |
|
Publish the Manuscript Online |
|
2023-04-25 23:32 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Matthew D McCormack, Natasha A Wahedna, David Aldulaimi and Peter Hawker |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Matthew D McCormack, MBChB, Doctor, Doctor, Department of Gastroenterology, South Warwickshire NHS Foundation Trust, Warwick Hospital, Lakin Road, Warwick CV34 5BW, United Kingdom. m.mccormack3@nhs.net |
| Key Words |
Dual biologic therapy; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Combination therapy; Biologic safety |
| Core Tip |
For patients with difficult to treat or refractory inflammatory bowel disease (IBD), biologic therapy and combination therapy with small molecule agents has helped improve patient outcomes and maintenance success. There is growing interest in the use of dual biologic therapy in IBD but published data remains limited. Whilst initial data suggests positive effects on reduction in morbidity, more studies are still required in this emerging area with further comparison of different biologic combinations and their safety profiles. |
| Publish Date |
2023-04-25 23:32 |
| Citation |
McCormack MD, Wahedna NA, Aldulaimi D, Hawker P. Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease. World J Clin Cases 2023; 11(12): 2621-2630 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i12/2621.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i12.2621 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
